68Ga–Prostate-Specific Membrane Antigen: A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma

Document Type: Case report

Authors

1 Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon

2 Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon

3 Department of Internal Medicine, Hematology/Oncology Division, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon

Abstract

68Ga Prostate-specific membrane antigen (PSMA) is an increasingly popular radiopharmaceutical tracer in prostate cancer and is becoming increasingly researched in other cancers such as breast cancer, renal cell carcinoma, glioblastoma multiforme, among others. Cholangiocarcinoma is the second most common primary hepatic malignant tumor; it is an aggressive tumor with a 5-year survival rate of less than 5 %. We herein report a case of primary cholangiocarcinoma detected on 68Ga-PSMA PET-CT conducted as part of follow up for prostate cancer and confirmed by biopsy and immunohistochemistry.

Keywords


  1. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41:11–20.
  2. Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, et al. ⁶⁸Ga-PSMA imaging of metastatic breast cancer.Eur J Nucl Med Mol Imaging. 2015 Aug; 42(9):1482-3.
  3. Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç, et al.(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.Eur J Nucl Med Mol Imaging. 2014 Jul; 41(7):1461-2.
  4. Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschorner R, Pichler B, et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma.Eur J Nucl Med Mol Imaging. 2015 Jan; 42(1):170-1.
  5. Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga] PSMA-HBED-CC PET/CT.Eur J Nucl Med Mol Imaging. 2015 Sep; 42(10):1622-3.
  6. Huang YT, Fong W, Thomas P. Rectal Carcinoma on 68Ga-PSMA PET/CT. ClinNucl Med. 2016 Mar; 41(3):e167-8.
  7. Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic NonSmall Cell Lung Cancer. ClinNucl Med. 2016 May; 41(5):414-6.
  8. Kanthan GL, Coyle L, Kneebone A, Schembri GP, Hsiao E. Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT. ClinNucl Med. 2016 Jun; 41(6):500-1.
  9. Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B, et al. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016 Apr; 43(4):795-6.
  10. Alipour R, Gupta S, Trethewey S. 68Ga-PSMA uptake in combined hepatocellular cholangiocarcinoma with skeletal metastases. Clin Nucl Med 2017; 42: e452–e453.
  11. Marafi, F., Usmani S., Esmail A. 68Ga–Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma.ClinNucl Med 2019; 44: e439–e441.
  12. Khan, SA, Tavolari, S, Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019; 39(Suppl. 1): 19– 31.
  13. Das J, Ray S, Tapadia R, Midha D, Mallick I. Prostate-specific Membrane Antigen-expressing Hepatic Lesion: Metastatic or Hepatocellular Carcinoma. Indian J Nucl Med. 2020; 35(1):58–60.
  14. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005; 128:1655–1667.
  15. Tang H, Wang Z, Lv W, Meng X. The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. Intractable Rare Dis Res. 2018; 7(2):106‐111.
  16. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192‐3198.
  17. Tosev G, Schuetz V, Nyarangi-Dix J, Stenzinger A, et al. Prostatic metastasis from intrahepatic cholangiocarcinoma. Urol Case Rep. 2018; 20:90‐91.